Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

The Dow Jones Industrial Average is down Wednesday morning with shares of UnitedHealth and Merck seeing the biggest drops for the price-weighted average.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...

The Tennessee Cattlemen’s Association (TCA) and Tennessee Cattlemen’s Youth Association (TCYA) recognized over 35 youth ...